EMEA-002519-PIP02-18

Key facts

Active substance
2-(2-(3-Butoxy-phenyl)-ethylamino)-N,N-dimethyl-acetamide hydrochloride
Therapeutic area
Psychiatry
Decision number
P/0215/2019
PIP number
EMEA-002519-PIP02-18
Pharmaceutical form(s)
Capsule (hard)
Condition(s) / indication(s)
Treatment of schizophrenia
Route(s) of administration
Oral use
Contact for public enquiries
Newron Pharmaceuticals SpA

E-mail: ravi@anand.ch
Tel. +41 793741364

Decision type
RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)

Decision

How useful was this page?

Add your rating